Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-10-27

FDA Approved: BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE — Supplemental Application (Acella Pharmaceuticals, LLC)

View source ↗

Summary

The FDA granted supplemental approval for Acella Pharmaceuticals' generic combination product containing brompheniramine maleate, pseudoephedrine hydrochloride,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE

Snippet

SUPPL AP for BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE (BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE, AND DEXTROMETHORPHAN HYDROBROMIDE)